INTEROR Plans to Strengthen Partnership within India's Pharma Supply Chain

INREROR, the French company, is planning to strengthen ties with Indian pharmaceutical manufacturers. It is their long-term plan to support global pharmaceutical clients over custom synthesis, technology transfer, and supply chain incorporation.

INTEROR declared an investment of €22 million to expand their manufacturing capacity in Calais, France. This is expected in serving regulated markets with specialized chemical processes. The company has started in India’s pharmaceutical area to integrate.

The company established a representative office in Mumbai recently, to serve as a local hub to identify and structure partnerships with Indian active chemical companies.

Geoffroy Waroqueaux, CEO of INTEROR, specified their decisions around capital deployment are driven by the requirements of regulated markets and client-specified technical needs. The company aims to collaborations instead of making direct investment in manufacturing or research and development areas in India. He also stated, “We are prioritizing partnerships that bring operational value, technology alignment, and regulatory compliance. For highly regulated markets such as Europe and the United States, many of our complex synthesis projects require infrastructure and oversight that we currently maintain in Europe.”

A discussion with several Indian companies about the potential co-development of complex intermediates and a long-term sourcing partnership with INTEROR. There are no formal joint ventures have been announced for now, but Waroqueaux confirmed that the company is willing to consider deeper industrial collaborations in the future.

In 2023, India’s pharmaceutical industry will be valued at around $50 billion by the leading suppliers of active pharmaceutical ingredients globally. India exported active pharmaceutical ingredients worth around $5 billion in FY2022-23, making it a primary partner for European companies looking for supply chain cost-effective manufacturing.

Waroqueaux said that it will depend on how well Indian partners align with INTEROR 'S expectations of regulatory governance, supply chain transparency and technical capabilities. Based on these, future investment decisions will be made.